

From 1 March 2020: Two brands of rituximab funded

What's changing?

There will be two brands of rituximab funded;

- **Riximyo** is the newly funded brand and will be funded for people using rituximab for all conditions apart from those with rheumatoid arthritis.
- **Mabthera** will remain funded for people with rheumatoid arthritis.

Between **1 March 2020 to 1 December 2020** we will be transitioning patients from Mabthera to Riximyo.

Rituximab will need to be prescribed by brand to ensure the correct brand is used.

- If a patient is unable to use the new brand of rituximab for a clinical reason, and it is safe to consider further treatment with rituximab, PHARMAC will consider a Named Patient Pharmaceutical Assessment (NPPA) application from a clinician to use the Mabthera brand of rituximab for an individual patient.

Haematology

Indication	Riximyo	Mabthera
Chronic lymphocytic leukaemia	Initial Funded from 1 March 2020 Renewal	Not funded from 1 March 2020 Not funded from 1 December 2020
Aggressive CD20 positive NHL	Initial Funded from 1 March 2020 Renewal	Not funded from 1 March 2020 Not funded from 1 December 2020
Haemophilia with inhibitors	Initial Funded from 1 March 2020 Renewal	Not funded from 1 March 2020 Not funded from 1 December 2020
Immune thrombocytopenic purpura (ITP)*	Initial Funded from 1 March 2020 Renewal	Not funded from 1 March 2020 Not funded from 1 December 2020
Indolent, low-grade lymphomas or hairy cell leukaemia*	Initial Funded from 1 March 2020 Renewal	Not funded from 1 March 2020 Not funded from 1 December 2020
Pure red cell aplasia (PRCA)*	Initial Funded from 1 March 2020 Renewal	Not funded from 1 March 2020 Not funded from 1 December 2020
Severe cold haemagglutinin disease (CHAD)*	Initial Funded from 1 March 2020 Renewal	Not funded from 1 March 2020 Not funded from 1 December 2020
Thrombotic thrombocytopenic purpura (TTP)*	Initial Funded from 1 March 2020 Renewal	Not funded from 1 March 2020 Not funded from 1 December 2020
Warm autoimmune haemolytic anaemia (warm AIHA)*	Initial Funded from 1 March 2020 Renewal	Not funded from 1 March 2020 Not funded from 1 December 2020

Nephrology

Indication	Riximyo	Mabthera
AMENDED ABO-incompatible organ transplant*	Initial Funded from 1 March 2020 Renewal	Not funded from 1 March 2020
AMENDED Antibody-mediated organ transplant rejection*	Initial Funded from 1 March 2020 Renewal	Not funded from 1 March 2020
Steroid dependent nephrotic syndrome (SDNS)* or frequently relapsing nephrotic syndrome (FRNS)*	Initial Funded from 1 March 2020 Renewal	Not funded from 1 March 2020 Not funded from 1 December 2020
Steroid resistant nephrotic syndrome (SRNS)*	Initial Funded from 1 March 2020 Renewal	Not funded from 1 March 2020 Not funded from 1 December 2020

Neurology

Indication	Riximyo	Mabthera
Severe Refractory Myasthenia Gravis	Initial Funded from 1 March 2020 Renewal	Not funded from 1 March 2020 Not funded from 1 December 2020
Neuromyelitis Optica Spectrum Disorder (NMOSD)	Initial Funded from 1 March 2020 Renewal	Not funded from 1 March 2020 Not funded from 1 December 2020
NEW Severe chronic inflammatory demyelinating polyneuropathy*	Initial Funded from 1 March 2020 Renewal	Not funded Not funded
NEW anti-NMDA receptor autoimmune encephalitis*	Initial Funded from 1 March 2020 Renewal	Not funded Not funded

Multiple speciality

Indication	Riximyo	Mabthera
Post-transplant*	Initial Funded from 1 March 2020 Renewal	Not funded from 1 March 2020 Not funded from 1 December 2020
ANCA associated vasculitis*	Initial Funded from 1 March 2020 Renewal	Not funded from 1 March 2020 Not funded from 1 December 2020
Treatment refractory systemic lupus erythematosus (SLE)*	Initial Funded from 1 March 2020 Renewal	Not funded from 1 March 2020 Not funded from 1 December 2020
AMENDED ABO-incompatible organ transplant*	Initial Funded from 1 March 2020 Renewal	Not funded from 1 March 2020
AMENDED Antibody-mediated organ transplant rejection*	Initial Funded from 1 March 2020 Renewal	Not funded from 1 March 2020
NEW Graft versus host disease*	Initial Funded from 1 March 2020 Renewal	Not funded
NEW Severe antisynthetase syndrome*	Initial Funded from 1 March 2020 Renewal	Not funded Not funded
Previous use	Initial Not funded from 1 March 2020 Renewal	Not funded from 1 March 2020

Rheumatology - only Mabthera brand is funded

Indication	Riximyo	Mabthera
Rheumatoid arthritis - TNF inhibitors contraindicated	Initial Not funded Renewal	Only funded brand - patent protection
Rheumatoid arthritis - prior TNF inhibitor use	Initial Not funded Renewal	Only funded brand - patent protection
Rheumatoid arthritis - re-treatment in 'partial responders' to rituximab	Initial Not funded Renewal	Only funded brand - patent protection
Rheumatoid arthritis - re-treatment in 'responders' to rituximab	Initial Not funded Renewal	Only funded brand - patent protection